Carbohydrate content of CTLA4 molecules

US10851150B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Kirk J. Leister · Fayetteville, US
• Eugene J. Schaefer · Westfield, US
• Ronald Charles Bates · Irvine, US
• Elizabeth A. Bramhall · Groton, US
• David Michael Didio · Syracuse, US
• Robert Donaldson · Southborough, US
• Alan R. Flesher · Lawrenceville, US
• Helen Gray Haggerty · Manlius, US
• David Henry Kirkley · East Syracuse, US
• John Malcolm Tabor · Syracuse, US
• Lee K. Tay · Princeton Junction, US
• Pallaiah Thammana · Manlius, US
• Ajoy Velayudhan · Cary, US
• David Edward Smolin · Pennington, US
• Reb J. Russell · Doylestown, US
• Thomas James Vanden Boom · Flemington, US
• Dean Woodrow Brownell · Oswego, US
• Jeffrey Schrimsher · Hillsborough, US
• Joyce Patricia Whitehead · Manlius, US

Key dates

• Filing date: Jul 24, 2018
• Grant date: Dec 1, 2020
• Expiry date: Aug 2, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.